Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)

Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis